Supplementary Table S3 from Palazestrant (OP-1250), A Complete Estrogen Receptor Antagonist, Inhibits Wild-type and Mutant ER-positive Breast Cancer Models as Monotherapy and in Combination
Year: 2024
Type: supplementary-materials
Abstract: RNASeq dataset of gene pathway changes following treatment with OP-1250, palbociclib and ribociclib in an MCF7 xenograft model.
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4392383768